Gene therapy for malignant glioma: Current clinical status

Molecular Therapy

Volumn 12, Issue 4, 2005, Pages 585-598

  Pulkkanen, Kalevi J ^a,b   Yla Herttuala, Seppo ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Brain tumor; Cancer; Clinical trial; Gene therapy; Malignant glioma

Indexed keywords

ADENOVIRUS VECTOR; ANGIOSTATIN; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; BETA GALACTOSIDASE; BETA INTERFERON; CYTOSINE DEAMINASE; DNA VACCINE; E1A PROTEIN; E1B PROTEIN; ENDOSTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FAS LIGAND; FLT3 LIGAND; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 4; LIPOSOME; NITROREDUCTASE; ONYX 015; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN; RETROVIRUS VECTOR; SOMATOMEDIN C RECEPTOR; THROMBOCYTE FACTOR 4; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN ANTIBODY;

ANTINEOPLASTIC ACTIVITY; CELL BASED GENE THERAPY; CLINICAL TRIAL; CONFUSION; DENDRITIC CELL; DRUG FEVER; FATIGUE; GENE TRANSFER; GLIOBLASTOMA; HEADACHE; HERPES SIMPLEX VIRUS; HUMAN; HYPONATREMIA; INTRACRANIAL HYPERTENSION; MENTAL DISEASE; NEUROTOXICITY; NONVIRAL GENE THERAPY; PROGNOSIS; REVIEW; SEIZURE; SIDE EFFECT; SURVIVAL RATE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS REPLICATION;

ADENOVIRIDAE; CLINICAL TRIALS; COMBINED MODALITY THERAPY; GENE THERAPY; GENETIC VECTORS; GLIOMA; HUMANS; IMMUNOTHERAPY; OLIGONUCLEOTIDES, ANTISENSE; ONCOLYTIC VIROTHERAPY;

SIMPLEXVIRUS;

EID: 25144436834     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2005.07.357     Document Type: Review

References (130)

1. J.F. Annegers B.S. Schoenberg H. Okazaki and L.T. Kurland Epidemiologic study of primary intracranial neoplasms Arch. Neurol. 38 1981 217-219
2. D.N. Louis E.C. Holland and J.G. Cairncross Glioma classification: A molecular reappraisal Am. J. Pathol. 159 2001 779-786
3. M. Salcman Supratentorial gliomas: Clinical features and surgical therapy (R.H. Wilkins and S.S. Rengachary, Eds.) Neurosurgery 1996 McGraw-Hill New York 777-778
4. H.A. Fine K.B. Dear J.S. Loeffler P.M. Black and G.P. Canellos Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults Cancer 71 1993 2585-2597
5. M.G. Castro et al. Current and future strategies for the treatment of malignant brain tumors Pharmacol. Ther. 98 2003 71-108
6. V.A. Levin et al. Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas J. Neurosurg. 63 1985 218-223
7. V.A. Levin et al. Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas Int. J. Radiat. Oncol. Biol. Phys. 32 1995 75-83
8. R. Stupp et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N. Engl. J. Med. 352 2005 987-996
9. A. Immonen et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: A randomised, controlled study Mol. Ther. 10 2004 967-972
10. K.J. Pulkkanen H. Sallinen K. Tyynela and S. Yla-Herttuala Cancer gene therapy - Current status in the clinics Gene Ther. Regul. 2 2004 219-274
11. R. Alemany C. Balague and D.T. Curiel Replicative adenoviruses for cancer therapy Nat. Biotechnol. 18 2000 723-727
12. D. Kirn R.L. Martuza and J. Zwiebel Replication-selective virotherapy for cancer: Biological principles, risk management and future directions Nat. Med. 7 2001 781-787
13. D. Banerjee and J.R. Bertino Myeloprotection with drug-resistance genes Lancet Oncol. 3 2002 154-158
14. P.R. Lowenstein Immunology of viral-vector-mediated gene transfer into the brain: An evolutionary and developmental perspective Trends Immunol. 23 2002 23-30
15. M. Aghi F. Hochberg and X.O. Breakefield Prodrug activation enzymes in cancer gene therapy J. Gene Med. 2 2000 148-164
16. A.C. Shah D. Benos G.Y. Gillespie and J.M. Markert Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas J. Neurooncol. 65 2003 203-226
17. P. Carmeliet and R.K. Jain Angiogenesis in cancer and other diseases Nature 407 2000 249-257
18. T. Taniguchi A. Rigg and N.R. Lemoine Targeting angiogenesis: Genetic intervention which strikes at the weak link of tumorigenesis Gene Ther. 5 1998 1011-1013
19. A. Matsuno and T. Nagashima Specific gene suppression using antisense strategy for growth suppression of glioma Med. Electron Microsc. 37 2004 158-161
20. D.W. Andrews et al. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas J. Clin. Oncol. 19 2001 2189-2200
21. M. Jansen P.C. Witt Hamer A.N. Witmer D. Troost and C.J. van Noorden Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas Brain Res. Brain Res. Rev. 45 2004 143-163
22. A. Nakamizo et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas Cancer Res. 65 2005 3307-3318
23. K. Shah et al. Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression Ann. Neurol. 57 2005 34-41
24. R.G. Vile and S.J. Russell Retroviruses as vectors Br. Med. Bull. 51 1995 12-30
25. N.G. Rainov and H. Ren Clinical trials with retrovirus mediated gene therapy - What have we learned? J. Neurooncol. 65 2003 227-236
26. M.A. Kay J.C. Glorioso and L. Naldini Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics Nat. Med. 7 2001 33-40
27. A.M. Sandmair et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses Hum. Gene Ther. 11 2000 2197-2205
28. X. Danthinne and M.J. Imperiale Production of first generation adenovirus vectors: A review Gene Ther. 7 2000 1707-1714
29. G. Romano P. Michell C. Pacilio and A. Giordano Latest developments in gene transfer technology: Achievements, perspectives, and controversies over therapeutic applications Stem Cells 18 2000 19-39
30. A. Kanerva and A. Hemminki Modified adenoviruses for cancer gene therapy Int. J. Cancer 110 2004 475-480
31. S. Varghese and S.D. Rabkin Oncolytic herpes simplex virus vectors for cancer virotherapy Cancer Gene Ther. 9 2002 967-978
32. M. Mizuno J. Yoshida P. Colosi and G. Kurtzman Adeno-associated virus vector containing the herpes simplex virus thymidine kinase gene causes complete regression of intracerebrally implanted human gliomas in mice, in conjunction with ganciclovir administration Jpn. J. Cancer Res. 89 1998 76-80
33. M.E. Wilcox et al. Reovirus as an oncolytic agent against experimental human malignant gliomas J. Natl. Cancer Inst. 93 2001 903-912
34. S.J. Russell RNA viruses as virotherapy agents Cancer Gene Ther. 9 2002 961-966
35. L.K. Csatary and T. Bakacs Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma JAMA 281 1999 1588-1589
36. H. Ren T. Boulikas K. Lundstrom A. Soling P.C. Warnke and N.G. Rainov Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki Forest virus vector carrying the human interleukin-12 gene - a phase I/II clinical protocol J. Neurooncol. 64 2003 147-154
37. D.S. Gridley M.L. Andres J. Li T. Timiryasova B. Chen and I. Fodor Evaluation of radiation effects against C6 glioma in combination with vaccinia virus-p53 gene therapy Int. J. Oncol. 13 1998 1093-1098
38. T.M. Timiryasova B. Chen P. Haghighat and I. Fodor Vaccinia virus-mediated expression of wild-type p53 suppresses glioma cell growth and induces apoptosis Int. J. Oncol. 14 1999 845-854
39. M. Gromeier S. Lachmann M.R. Rosenfeld P.H. Gutin and E. Wimmer Intergeneric poliovirus recombinants for the treatment of malignant glioma Proc. Natl. Acad. Sci. USA 97 2000 6803-6808
40. C.A. Jackson C. Cobbs J.D. Peduzzi M. Novak and C.D. Morrow Repetitive intrathecal injections of poliovirus replicons result in gene expression in neurons of the central nervous system without pathogenesis Hum. Gene Ther. 12 2001 1827-1841
41. L. Naldini U. Blömer F.H. Gage D. Trono and I.M. Verma Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector Proc. Natl. Acad. Sci. USA 93 1996 11382-11388
42. C.S. Stein and B.L. Davidson Gene transfer to the brain using feline immunodeficiency virus-based lentivirus vectors Methods Enzymol. 346 2002 433-454
43. M. Thomas and A.M. Klibanov Non-viral gene therapy: Polycation-mediated DNA delivery Appl. Microbiol. Biotechnol. 62 2003 27-34
44. T. Niidome and L. Huang Gene therapy progress and prospects: Nonviral vectors Gene Ther. 9 2002 1647-1652
45. A.G. Schatzlein Non-viral vectors in cancer gene therapy: Principles and progress Anticancer Drugs 12 2001 275-304
46. T. Yoshida M. Mizuno K. Taniguchi N. Nakayashiki T. Wakabayashi and J. Yoshida Rat glioma cell death induced by cationic liposome-mediated transfer of the herpes simplex virus thymidine kinase gene followed by ganciclovir treatment J. Surg. Oncol. 76 2001 19-25
47. J. Yoshida and M. Mizuno Clinical gene therapy for brain tumors: liposomal delivery of anticancer molecule to glioma J. Neurooncol. 65 2003 261-267
48. E.H. Oldfield Z. Ram K.W. Culver R.M. Blaese H.L. DeVroom and W.F. Anderson Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir Hum. Gene Ther. 4 1993 39-69
49. C. Raffel et al. Gene therapy for the treatment of recurrent pediatric malignant astrocytomas with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system Hum. Gene Ther. 5 1994 863-890
50. L.E. Kun et al. Stereotactic injection of herpes simplex thymidine kinase vector producer cells (PA317-G1Tk1SvNa.7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors Hum. Gene Ther. 6 1995 1231-1255
51. S.M. Freeman et al. The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified Cancer Res. 53 1993 5274-5283
52. M. Mesnil C. Piccoli G. Tiraby K. Willecke and H. Yamasaki Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins Proc. Natl. Acad. Sci. USA 93 1996 1831-1835
53. Z. Ram et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells Nat. Med. 3 1997 1354-1361
54. D. Klatzmann et al. A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma Hum. Gene Ther. 9 1998 2595-2604
55. N. Shand et al. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European - Canadian Study Group Hum. Gene Ther. 10 1999 2325-2335
56. C.A. Valery et al. Long-term survival after gene therapy for a recurrent glioblastoma Neurology 58 2002 1109-1112
57. M. Izquierdo et al. Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy Gene Ther. 3 1996 491-495
58. M. Izquierdo et al. Gene therapy in brain tumours: Implications of the size of glioblastoma on its curability Acta Neurochir. Suppl. 68 1997 111-117
59. R.J. Packer et al. Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration J. Neurosurg. 92 2000 249-254
60. G. Palu et al. Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: A pilot study in humans Gene Ther. 6 1999 330-337
61. M.D. Prados et al. Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: A phase I/II multi-institutional trial J. Neurooncol. 65 2003 269-278
62. A.M. Puumalainen et al. Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses Hum. Gene Ther. 9 1998 1769-1774
63. G.R. Harsh et al. Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: A gene-marking and neuropathological study J. Neurosurg. 92 2000 804-811
64. N.G. Rainov A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme Hum. Gene Ther. 11 2000 2389-2401
65. S.L. Eck et al. Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: A phase I trial Hum. Gene Ther. 7 1996 1465-1482
66. T.W. Trask et al. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors Mol. Ther. 1 2000 195-203
67. K.D. Judy and S.L. Eck The use of suicide gene therapy for the treatment of malignancies of the brain (E.C. Lattime L.C. Stanton, Eds.) Gene Therapy of Cancer 2002 Academic Press San Diego 505-512
68. I.M. Germano J. Fable S.H. Gultekin and A. Silvers Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: Preliminary results of a phase I trial in patients with recurrent malignant gliomas J. Neurooncol. 65 2003 279-289
69. P.S. Smitt M. Driesse J. Wolbers M. Kros and C. Avezaat Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir Mol. Ther. 7 2003 851-858
70. A. Jacobs et al. Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas Lancet 358 2001 727-729
71. J. Voges et al. Liposomal gene therapy with the herpes simplex thymidine kinase gene/ganciclovir system for the treatment of glioblastoma multiforme Hum. Gene Ther. 13 2002 675-685
72. W.D. Hunter et al. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation of intracerebral injection in nonhuman primates J. Virol. 73 1999 6319-6326
73. P. Sundaresan W.D. Hunter R.L. Martuza and S.D. Rabkin Attenuated, replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation in mice J. Virol. 74 2000 3832-3841
74. T. Mineta S.D. Rabkin T. Yazaki W.D. Hunter and R.L. Martuza Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas Nat. Med. 1 1995 938-943
75. J.M. Markert et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial Gene Ther. 7 2000 867-874
76. E.A. McKie S.M. Brown A.R. MacLean and D.I. Graham Histopathological responses in the CNS following inoculation with a non-neurovirulent mutant (1716) of herpes simplex virus type 1 (HSV 1): Relevance for gene and cancer therapy Neuropathol. Appl. Neurobiol. 24 1998 367-372
77. R. Rampling et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma Gene Ther. 7 2000 859-866
78. V. Papanastassiou et al. The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: A proof of principle study Gene Ther. 9 2002 398-406
79. J. Harland V. Papanastassiou and S.M. Brown HSV1716 persistence in primary human glioma cells in vitro Gene Ther. 9 2002 1194-1198
80. S. Harrow et al. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: Safety data and long-term survival Gene Ther. 11 2004 1648-1658
81. J.P. Lamont J. Nemunaitis J.A. Kuhn S.A. Landers and T.M. McCarty A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience) Ann. Surg. Oncol. 7 2000 588-592
82. F.R. Khuri et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nat. Med. 6 2000 879-885
83. J. Nemunaitis et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer J. Clin. Oncol. 19 2001 289-298
84. T. Reid et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints Cancer Res. 62 2002 6070-6079
85. O. Hamid et al. Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer J. Clin. Oncol. 21 2003 1498-1504
86. D. Makower et al. Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies Clin. Cancer Res. 9 2003 693-702
87. E.A. Chiocca et al. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting Mol. Ther. 10 2004 958-966
88. O. Bogler H.J. Huang P. Kleihues and W.K. Cavenee The p53 gene and its role in human brain tumors Glia 15 1995 308-327
89. H. Li et al. Intracerebral adenovirus-mediated p53 tumor suppressor gene therapy for experimental human glioma Clin. Cancer Res. 5 1999 637-642
90. F.F. Lang W.K. Yung R. Sawaya and P.J. Tofilon Adenovirus-mediated p53 gene therapy for human gliomas Neurosurgery 45 1999 1093-1104
91. F.F. Lang et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: Biological and clinical results J. Clin. Oncol. 21 2003 2508-2518
92. A. Natsume M. Mizuno Y. Ryuke and J. Yoshida Antitumor effect and cellular immunity activation by murine interferon-beta gene transfer against intracerebral glioma in mouse Gene Ther. 6 1999 1626-1633
93. A. Natsume K. Tsujimura M. Mizuno T. Takahashi and J. Yoshida IFN-beta gene therapy induces systemic antitumor immunity against malignant glioma J. Neurooncol. 47 2000 117-124
94. J. Yoshida et al. Human gene therapy for malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) by in vivo transduction with human interferon beta gene using cationic liposomes Hum. Gene Ther. 15 2004 77-86
95. H. Okada et al. Gene therapy of malignant gliomas: A phase I study of IL-4-HSV-TK gene-modified autologous tumor to elicit an immune response Hum. Gene Ther. 11 2000 637-653
96. S.L. Eck et al. Treatment of recurrent or progressive malignant glioma with a recombinant adenovirus expressing human interferon-beta (H5.010CMVhIFN-beta): A phase I trial Hum. Gene Ther. 12 2001 97-113
97. H. Okada et al. Gene therapy of malignant gliomas: A pilot study of vaccination with irradiated autologous glioma and dendritic cells admixed with IL-4 transduced fibroblasts to elicit an immune response Hum. Gene Ther. 12 2001 575-595
98. M. Resnicoff et al. Regression of C6 rat brain tumors by cells expressing an antisense insulin-like growth factor I receptor RNA J. Exp. Ther. Oncol. 1 1996 385-389
99. D.R. Macdonald T.L. Cascino S.C. Schold Jr. and J.G. Cairncross Response criteria for phase II studies of supratentorial malignant glioma J. Clin. Oncol. 8 1990 1277-1280
100. D. Barba J. Hardin M. Sadelain and F.H. Gage Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors Proc. Natl. Acad. Sci. USA 91 1994 4348-4352
101. Z. Long et al. Molecular evaluation of biopsy and autopsy specimens from patients receiving in vivo retroviral gene therapy Hum. Gene Ther. 10 1999 733-740
102. N.G. Rainov et al. Retrovirus-mediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ ganciclovir paradigm Cancer Gene Ther. 3 1996 99-106
103. D.W. Russell M.S. Berger and A.D. Miller The effects of human serum and cerebrospinal fluid on retroviral vectors and packaging cell lines Hum. Gene Ther. 6 1995 635-641
104. T. Inamura T. Nomura R.T. Bartus and K.L. Black Intracarotid infusion of RMP-7, a bradykinin analog: A method for selective drug delivery to brain tumors J. Neurosurg. 81 1994 752-758
105. D.R. LeMay et al. Intravenous RMP-7 increases delivery of ganciclovir into rat brain tumors and enhances the effects of herpes simplex virus thymidine kinase gene therapy Hum. Gene Ther. 9 1998 989-995
106. W.A. Freije et al. Gene expression profiling of gliomas strongly predicts survival Cancer Res. 64 2004 6503-6510
107. F.A. Nunes E.E. Furth J.M. Wilson and S.E. Raper Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: Safety of readministration Hum. Gene Ther. 10 1999 2515-2526
108. S.E. Raper et al. Fatal systemic inflammatory response syndrome in an ornithine transcarbamylase deficient patient following adenoviral gene transfer Mol. Genet. Metab. 80 2003 148-158
109. M.J. Wood A.P. Byrnes D.W. Pfaff S.D. Rabkin and H.M. Charlton Inflammatory effects of gene transfer into the CNS with defective HSV-1 vectors Gene Ther. 1 1994 283-291
110. A.P. Byrnes J.E. Rusby M.J. Wood and H.M. Charlton Adenovirus gene transfer causes inflammation in the brain Neuroscience 66 1995 1015-1024
111. C.E. Thomas G. Schiedner S. Kochanek M.G. Castro and P.R. Lowenstein Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: Toward realistic long-term neurological gene therapy for chronic diseases Proc. Natl. Acad. Sci. USA 97 2000 7482-7487
112. R.A. Dewey et al. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials Nat. Med. 5 1999 1256-1263
113. A.J. Zermansky et al. Towards global and long-term neurological gene therapy: Unexpected transgene dependent, high-level, and widespread distribution of HSV-1 thymidine kinase throughout the CNS Mol. Ther. 4 2001 490-498
114. R.G. Vile S.J. Russell and N.R. Lemoine Cancer gene therapy: Hard lessons and new courses Gene Ther. 7 2000 2-8
115. N. Bessis F.J. GarciaCozar and M.C. Boissier Immune responses to gene therapy vectors: Influence on vector function and effector mechanisms Gene Ther. 11 2004 S10-S17
116. H. Wakimoto P.R. Johnson D.M. Knipe and E.A. Chiocca Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells Gene Ther. 10 2003 983-990
117. C.E. Thomas G. Schiedner S. Kochanek M.G. Castro and P.R. Lowenstein Preexisting antiadenoviral immunity is not a barrier to efficient and stable transduction of the brain, mediated by novel high-capacity adenovirus vectors Hum. Gene Ther. 12 2001 839-846
118. L. Zou H. Zhou L. Pastore and K. Yang Prolonged transgene expression mediated by a helper-dependent adenoviral vector (hdAd) in the central nervous system Mol. Ther. 2 2000 105-113
119. S. Yip et al. Neural stem cell biology may be well suited for improving brain tumor therapies Cancer J. 9 2003 189-204
120. K. Nakamura et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model Gene Ther. 11 2004 1155-1164
121. C. Grana et al. Pretargeted adjuvant radioimmunotherapy with yttrium-90 - biotin in malignant glioma patients: A pilot study Br. J. Cancer 86 2002 207-212
122. P. Lehtolainen et al. Targeting of biotinylated compounds to its target tissue using a low-density lipoprotein receptor-avidin fusion protein Gene Ther. 10 2003 2090-2097
123. Z.M. Qian H. Li H. Sun and K. Ho Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway Pharmacol. Rev. 54 2002 561-587
124. D. Nanda R. Vogels M. Havenga C.J. Avezaat A. Bout and P.S. Smitt Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase Cancer Res. 61 2001 8743-8750
125. S. Ali et al. Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression Mol. Ther. 10 2004 1071-1084
126. E.J. Boviatsis et al. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene Cancer Res. 54 1994 5745-5751
127. M. Chase R.Y. Chung and E.A. Chiocca An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy Nat. Biotechnol. 16 1998 444-448
128. R.G. Blasberg and J.G. Tjuvajev Herpes simplex virus thymidine kinase as a marker/reporter gene for PET imaging of gene therapy Q. J. Nucl. Med. 43 1999 163-169
129. S.S. Gambhir et al. Imaging transgene expression with radionuclide imaging technologies Neoplasia 2 2000 118-138
130. C. Nyberg-Hoffman et al. Sensitivity and reproducibility in adenoviral infectious titer determination Nat. Med. 3 1997 808-811